Clinical Trial Update: Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ADC4022 co-administered with Budesonide for pulmonary inflammation in moderate-to-severe COPD. The study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ADC4022 (ADC4022)
• Budesonide (BUDESONIDE)

Snippet

Sponsor: Pulmagen Therapeutics | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED